Tags

Type your tag names separated by a space and hit enter

Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
Leuk Res. 2009 Jul; 33(7):e73-4.LR

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Letter

Language

eng

PubMed ID

19108887

Citation

Grammatico, S, et al. "Increasing the BCR-ABL Expression Levels And/or the Occurrence of ABL Point Mutations Does Not Always Predict Resistance to Imatinib Mesylate in BCR-ABL Positive Acute Lymphoblastic Leukemia." Leukemia Research, vol. 33, no. 7, 2009, pp. e73-4.
Grammatico S, Elia L, Peluso AL, et al. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia. Leuk Res. 2009;33(7):e73-4.
Grammatico, S., Elia, L., Peluso, A. L., Pedace, L., Matarazzo, M., Vitale, A., Rago, A., Pane, F., Foà, R., & Cimino, G. (2009). Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia. Leukemia Research, 33(7), e73-4. https://doi.org/10.1016/j.leukres.2008.11.009
Grammatico S, et al. Increasing the BCR-ABL Expression Levels And/or the Occurrence of ABL Point Mutations Does Not Always Predict Resistance to Imatinib Mesylate in BCR-ABL Positive Acute Lymphoblastic Leukemia. Leuk Res. 2009;33(7):e73-4. PubMed PMID: 19108887.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia. AU - Grammatico,S, AU - Elia,L, AU - Peluso,A L, AU - Pedace,L, AU - Matarazzo,M, AU - Vitale,A, AU - Rago,A, AU - Pane,F, AU - Foà,R, AU - Cimino,G, Y1 - 2008/12/23/ PY - 2008/10/16/received PY - 2008/10/31/revised PY - 2008/11/01/accepted PY - 2008/12/26/entrez PY - 2008/12/26/pubmed PY - 2009/5/29/medline SP - e73 EP - 4 JF - Leukemia research JO - Leuk Res VL - 33 IS - 7 SN - 1873-5835 UR - https://www.unboundmedicine.com/medline/citation/19108887/Increasing_the_BCR_ABL_expression_levels_and/or_the_occurrence_of_ABL_point_mutations_does_not_always_predict_resistance_to_Imatinib_Mesylate_in_BCR_ABL_positive_acute_lymphoblastic_leukemia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0145-2126(08)00489-X DB - PRIME DP - Unbound Medicine ER -